Song Xiaotong, Li Jie
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Evid Based Complement Alternat Med. 2022 Apr 15;2022:9942373. doi: 10.1155/2022/9942373. eCollection 2022.
Immunotherapy is a promising breast cancer treatment. Nonetheless, tumor heterogeneity and the interaction between immune cells in the tumor microenvironment limit its effectiveness. Formononetin-extracted from the Chinese medicinal plant -can inhibit tumor growth, induce apoptosis and angiogenesis, and reverse multidrug resistance. However, its efficacy and mechanism of action on the immune cells in breast cancer remain unclear. Here, we screened immune-related genes of breast cancer to determine the potential of formononetin as a therapeutic.
GSE103512 and GSE139038 breast cancer microarray data and immune-related gene data were obtained from the GEO and ImmPort databases, respectively, to analyze the differentially expressed immune-related genes (IRGs) in breast cancer tissues compared with normal breast tissues. Protein-protein interaction (PPI) analysis was performed using the STRING database to screen differentially expressed IRGs based on the topological parameters. The Kaplan-Meier test was applied to detect differentially expressed IRGs associated with breast cancer survival, and the interaction of formononetin with differentially expressed IRGs was analyzed using molecular docking. Finally, the relationship between differentially expressed IRGs and breast cancer immune cell infiltration was analyzed using the TIMER2.0 database.
A total of 29 differentially expressed IRGs of breast cancer were screened through GEO and ImmPort databases and 10 key differentially expressed IRGs based on the topological parameters from the PPI network. Among these, CXCL12, ESR1, IGF1, and FOS were associated with breast cancer survival. Furthermore, IGF1, ESR1, and CXCL12 were found to have stable binding sites for formononetin. These genes were associated with substantial immune cell infiltration in breast cancer tissues.
In conclusion, formononetin may exert antitumor effects by acting on CXCL12, ESR1, and IGF1 and may have a potential synergistic effect with immune checkpoint inhibitors.
免疫疗法是一种很有前景的乳腺癌治疗方法。然而,肿瘤异质性以及肿瘤微环境中免疫细胞之间的相互作用限制了其疗效。从中药植物中提取的芒柄花素可抑制肿瘤生长、诱导凋亡和血管生成,并逆转多药耐药性。然而,其对乳腺癌免疫细胞的疗效和作用机制仍不清楚。在此,我们筛选了乳腺癌的免疫相关基因,以确定芒柄花素作为一种治疗药物的潜力。
分别从GEO和ImmPort数据库中获取GSE103512和GSE139038乳腺癌微阵列数据及免疫相关基因数据,以分析乳腺癌组织与正常乳腺组织中差异表达的免疫相关基因(IRGs)。使用STRING数据库进行蛋白质-蛋白质相互作用(PPI)分析,以基于拓扑参数筛选差异表达的IRGs。应用Kaplan-Meier检验检测与乳腺癌生存相关的差异表达IRGs,并使用分子对接分析芒柄花素与差异表达IRGs的相互作用。最后,使用TIMER2.0数据库分析差异表达IRGs与乳腺癌免疫细胞浸润之间的关系。
通过GEO和ImmPort数据库共筛选出29个乳腺癌差异表达IRGs,并基于PPI网络的拓扑参数筛选出10个关键差异表达IRGs。其中,CXCL12、ESR1、IGF1和FOS与乳腺癌生存相关。此外,发现IGF1、ESR1和CXCL12对芒柄花素有稳定的结合位点。这些基因与乳腺癌组织中大量免疫细胞浸润相关。
总之,芒柄花素可能通过作用于CXCL12、ESR1和IGF1发挥抗肿瘤作用,并且可能与免疫检查点抑制剂具有潜在的协同作用。